Farid Ramy reported grant involving 16,000 derivative units of Vir Biotechnology, Inc. at $0.00 for $0 on May 27, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed May 28, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
16,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
16,000Direct
Trade date
May 27, 2026Grant
Filed
May 28, 2026, 7:24 PM ET1-day reporting delay
Accession
0001628280-26-038962Code A · Transaction 387327
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 27, 2026Grant8,000$0.00$0Trade 387326
2 transaction rows in this filing. Joint filers share the same rows.

VIR price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VIR · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +11%1w ago −7%1d ago −1.8%
Returns since7d −4.2%30d +5%90d +16%180d1y

Footnotes in full

F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: The RSUs will vest in full on May 27, 2027. F3: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.